1
|
Varela C, Nassr M, Razak A, Yang SY, Kim NK. Postoperative bleeding in essential thrombocytosis patients with colorectal cancer: Case report and literature review. Int J Surg Case Rep 2021; 86:106374. [PMID: 34507190 PMCID: PMC8433273 DOI: 10.1016/j.ijscr.2021.106374] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 08/26/2021] [Accepted: 09/02/2021] [Indexed: 11/28/2022] Open
Abstract
Introduction and importance Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by increased platelet count and a high risk of bleeding or thrombotic events due to platelet dysfunction. Patients with ET are treated according to their risk of complications with cytoreductive or anti-aggregant treatment. Neither guidelines for oncologic patients nor perioperative management of patients with ET have been determined. Case presentation A 41-year-old female patient with ET who had alternating constipation and diarrhea was referred after a screening colonoscopy diagnosing a locally advanced rectosigmoid junction colon adenocarcinoma with liver metastases. Systemic preoperative chemotherapy was indicated. The patient underwent laparoscopic low anterior resection plus volume-preserving right lobectomy of the liver. Postoperative bleeding of the internal iliac artery (IIA) associated with hematoma at the lower pelvic cavity was diagnosed and treated by interventional radiology; the patient was discharged without other complications 16 days after surgery. Clinical discussion ET has been related to the development of hematologic complications or second non-hematologic malignancies. A systematic review was conducted to seek guidance for the management of such patients in the perioperative period. Special perioperative care must be taken, and complications management should avoid further hemorrhages or cloth formation. Conclusion Under oncologic and hematological guidance, minimally invasive surgery and non-invasive management of complications are advised in the lack of published perioperative management guidelines of ET patients with colorectal cancer. Essential thrombocythemia (ET) is a rare clonal myeloproliferative disorder. ET can manifest as hemorrhage, thrombosis, and functional microvascular symptoms. Cytoreductive treatment and anti-aggregants are indicated in ET with a high risk of complications. Colorectal cancer, with its surgical and oncologic treatment, may increase the risk of adverse vascular events. Perioperative management of patients with ET has not been determined.
Collapse
Affiliation(s)
- Cristopher Varela
- Coloproctology Unit, Department of General Surgery, Hospital Dr. Domingo Luciani, Venezuela
| | - Manar Nassr
- Department of Colorectal Surgery, General Surgery Division, Royal Hospital, Oman
| | | | - Seung Yoon Yang
- Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - Nam Kyu Kim
- Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
| |
Collapse
|
2
|
Andersson BS. Essential Thrombocythemia: Diagnosis and Treatment, with Special Emphasis on the Use of Anagrelide. Hematology 2013; 7:173-7. [PMID: 12243981 DOI: 10.1080/10245330290028597] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
3
|
Bidot CJ, Jy W, Horstman LL, Ahn ER, Bidot L, Fontana V, Ahn YS. Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia. Hematology 2013; 10:451-6. [PMID: 16321809 DOI: 10.1080/10245330500226860] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
INTRODUCTION Risk factors for thrombosis (TB) in thrombocythaemia (TC) associated with myeloproliferative disorder (MPD) are not well defined. METHODS We measured antiphospholipid antibodies (APLA) in 35 patients with TC associated with MPD. Fourteen had TB and 21 did not. We assayed IgG and IgM APLA by ELISA for 6 antigens: beta2GP1, cardiolipin (CL), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE) and FVII/VIIa, together with markers of activation of platelets (CD62P) and endothelium [endothelial microparticles (EMP)]. RESULTS At least one positive APLA was detected in 66% of TC patients overall. The incidence was significantly higher in the TB subgroup (92.8%) than non-TB (47.6%, p < 0.05). Multiple APLA (positive for more than one antigen) were also more frequent in TB, for both IgG and IgM, for all 6 antigens tested (p < 0.05). However, IgM APLA predominated, being about 2-fold more frequently positive than IgG for all 6 antigens. Platelet CD62P was significantly higher in the TB group (p < 0.05). EMP did not differ between TB and non-TB. The most frequent thrombotic complication was recurring ischemic cerebral vascular accidents (ICVA), leading to progressive cognitive impairment. Venous TB often developed at unusual sites. Recurring and reversible TB were common features in TC. SUMMARY This study suggests that APLA and platelet activation are risk factors for TB in TC. APLA are prevalent in TC, and IgM APLA predominated over IgG. Activation of platelets but not of endothelium may be consistent with the reversible and recurrent features of TB in TC.
Collapse
Affiliation(s)
- Carlos J Bidot
- Wallace H Coulter Platelet Laboratory, Division of Hematology/Oncology, University of Miami School of Medicine, Miami, FL, 33136, USA
| | | | | | | | | | | | | |
Collapse
|
4
|
Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol 2008. [DOI: 10.1111/j.1365-2141.2000.02430.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
5
|
Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol 2000. [DOI: 10.1046/j.1365-2141.2000.02430.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
6
|
Abstract
Essential thrombocythemia (ET) is often associated with thrombotic and hemorrhagic complications, mostly at platelet counts exceeding 600 x 10(9)/L. There are, however, a few reports of such complications in ET at considerably lower platelet levels and the therapeutic approach to affected patients with relatively low platelet counts is still controversial. In the present study, the first to directly address the issue of hemostatic manifestations at relatively low platelet counts, we have determined the lowest platelet counts associated with such manifestations in 56 consecutive ET patients. Clinical manifestations related to ET were recorded in 46 (82%) patients. Of the symptomatic patients, 32 (70%) had symptoms at platelet counts lower than 600 x 10(9)/L, 23 (50%) at counts lower than 500 x 10(9)/L, 10 (22%) at counts lower than 400 x 10(9)/L, and 6 patients (13%) at platelet counts as low as 300-350 x 10(9)/L. Severe complications occurred at platelet counts lower than 600 x 10(9)/L in 10 patients (22%), lower than 500 x 10(9)/L in 7 (15%), and at lower than 400 x 10(9)/L in 2 (4%). Thrombotic neurologic symptoms were the most common (31 patients, 67%), followed by peripheral vascular symptoms (17 patients, 37%); hemorrhagic complications were relatively rare (3 patients, 7%). In most cases, cessation or improvement of clinical manifestations was observed only after further reduction in platelet counts. In conclusion, thrombotic manifestations, including severe ones, are not uncommon in ET at relatively low platelet counts. We recommend that symptomatic patients with relatively low platelet counts be treated and the platelet counts further reduced well into the lower normal range.
Collapse
Affiliation(s)
- A Regev
- Department of Internal Medicine E, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel
| | | | | | | |
Collapse
|
7
|
Yan L, Elkassar N, Gardin C, Briere J. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia. Leuk Lymphoma 1996; 22 Suppl 1:31-40. [PMID: 8951770 DOI: 10.3109/10428199609074358] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The development of techniques permitting in vitro growth of human megakaryocytes progenitors and more recently identification of the proto oncogene c-mpl (Mpl-R) and its ligand (Mpl-L) have created new opportunities for studying pathophysiology of E.T. Plasma or serum of E.T. patients was unable to overestimulate MK colony formation by normal bone marrow cells. Significant increases in circulating CFU MK in E.T. patients have been repeatedly observed while in E.T. marrow, due to inappropriate sampling, colony number was not significantly different from normal. Spontaneous colony formation is observed in approximately 100% bone marrow and 85% blood from E.T. patients. Spontaneous colony formation persisted in plasma clot assay without added plasma or serum and in serum free agar cultures but only at a slightly lower rate than in plasma clot. Spontaneous colony formation in culture condition without plasma and serum were never observed with normal bone marrow and blood. Spontaneous MK growth was observed in a higher proportion of E.T. patients than erythroid colony formation but both phenomenon can occur in about 50% of the patients. CFU MK colony formation disappeared in serum free cultures using highly purified CD 34 cells. MK development is not completely independent of regular control. An hypersensitivity of E.T. MK progenitors to growth factors known to stimulate normal hematopoiesis (IL3.IL6, GM CSF, has been shown as well as a decreased sensitivity to negative regulators (TGF beta), has been suggested. The number of spontaneous MK colonies was not significantly decreased by added anti IL3, IL6 or anti GM CSF, antibodies in culture medium. Pre incubation of blood non adherent mononuclear cells of E.T. patients with antisense oligonucleotides to c-mpl significantly decreased the cloning efficiency of spontaneous megakaryocyte growth as compared to the introduction of scrambled oligomers. Finally m RNA expression of the Mpl-L (TPO) was not formed in MK spontaneously grown in serum free liquid cultures after 12 days. These results suggest that human c-mpl proto oncogene may be implicated in the pathway of spontaneous megakaryocytopoiesis in MPD but an absence of autocrine-stimulation by TPO of spontaneous growth in MPD. Analysis of peripheral blood cell clonality was performed in 55 E.T. patients using either the DNA methylation pattern of the androgen receptor (AR) gene or mRNA transcripts of G6PD or IDS genes. 51 out of 55 patients were informative. Non random X inactivation was found on unfractioned blood in 73% as compared with 23% in normal females (skewed Lyonisation). In 12 patients monoclonality of hematopoiesis was definitely confirmed by recording polyclonality of the mononuclear fraction or of T lymphocytes. In 4 patients monoclonal hematopoiesis was limited to platelets, 7 patients remained polyclonal in whole blood and all cellular fractions studied. MK colony formation (provided that the serum free agar culture system is clearly standardised) and clonality studies on whole blood or granulocyte, T lymphocyte and platelet fractions may be proposed as positive criteria for diagnosis of E.T.
Collapse
Affiliation(s)
- L Yan
- Haematology Division, Hospital Beaujon, Clichy, France
| | | | | | | |
Collapse
|
8
|
Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer 1995; 75:471-7. [PMID: 7812918 DOI: 10.1002/1097-0142(19950115)75:2<471::aid-cncr2820750210>3.0.co;2-b] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Leukemic transformation of polycythemia vera (PV) and essential thrombocythemia (ET) is influenced by the therapeutic modalities used. A high incidence of leukemic transformation was found among patients with PV or ET treated with an alkylating agent, carboquone (CQ). The study was conducted to assess the causal relationship between CQ and leukemic transformation of PV and ET. METHOD Twenty-seven patients with PV and 29 with ET diagnosed from January 1975 to August 1993 and whose clinical course could be followed comprised the members of this retrospective study. The patients were examined for the treatment administered, hematologic data, vascular complications, malignancies including leukemia, and eventual outcome. RESULTS Eighteen patients with PV and 16 with ET were treated with CQ. The follow-up was 51-209 months for patients with PV and 28-176 months for those with ET. Three patients with PV (17% of those treated with CQ) and 5 with ET (31% of those treated with CQ) had subsequent transformation to acute leukemia. The median period until transformation of patients with PV was 94 months, whereas the median follow-up of patients without transformation was 146 months (P < 0.01). The median total days of CQ administration and the median total dose of CQ were 2022 days and 1226 mg, respectively, for the patients with transformation and 1051 days (P < 0.05) and 435 mg (P < 0.01), respectively, for those without transformation. Likewise, the median follow-ups for patients with ET with or without transformation were 130 and 90 months, respectively; the difference was insignificant. The median total days of CQ administration and the median total dose of CQ were 2075 days and 1019 mg, respectively, for patients with transformation and 571 days (P < 0.05) and 231 mg (P < 0.01), respectively, for those without transformation. These observations suggest that CQ may be involved in the leukemic transformation of PV and ET. The subtypes of leukemia transformed from PV corresponded to M2 in two patients and to M4 in one. All five patients with ET were found to have megakaryoblastic features at transformation, and three were diagnosed as having leukemic subtype M7. Chromosomal abnormalities were found in all five patients (two PV and three ET) examined after leukemic transformation, showing multiple and complex abnormalities in four. CONCLUSION Showing that both the total days of CQ administration and the total dose of CQ were larger for patients with PV or ET whose disease subsequently transformed to leukemia, with this study, a possible causal role of CQ in leukemic transformation of PV and ET is suggested.
Collapse
Affiliation(s)
- T Higuchi
- Division of Hematology, Showa University Fujigaoka Hospital, Yokohama, Japan
| | | | | | | | | | | |
Collapse
|
9
|
Tsukamoto N, Morita K, Maehara T, Okamoto K, Sakai H, Karasawa M, Naruse T, Omine M. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol 1994; 86:253-8. [PMID: 7911034 DOI: 10.1111/j.1365-2141.1994.tb04723.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The restriction fragment length polymorphisms (RFLP) of the X-chromosome phosphoglycerate kinase (PGK) and hypoxanthine phosphoribosyltransferase (HPRT) genes were used to study the clonal basis of the chronic myeloproliferative disorders (CMPD). Analyses were performed on granulocyte and T-lymphocyte fractions obtained from 24 females; 13 had essential thrombocythaemia (ET), eight polycythaemia vera (PV) and three myelofibrosis with myeloid metaplasia (MMM). All 24 of these patients had monoclonal patterns of X-inactivation in the granulocyte fraction. For the T-lymphocyte fraction, non-clonal patterns of X-inactivation were observed in 8/13 patients with ET, 7/8 with PV and 1/3 with MMM, while the remaining eight subjects were found to have monoclonal patterns of X-inactivation. Our findings suggest that the majority of the CMPD in these patients originated from a relatively committed progenitor cell without the capacity to differentiate into T cells, and convincingly demonstrated heterogeneity of lineage involvement.
Collapse
Affiliation(s)
- N Tsukamoto
- Third Department of Internal Medicine, Gunma University School of Medicine, Japan
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
The nonleukemic chronic myeloproliferative disorders, polycythemia vera, essential thrombocytosis, and myeloid metaplasia with myelofibrosis, are clonal disorders with similar but distinct clinical and laboratory findings. This review will discuss the diagnostic criteria for each disease, the variable clinical picture, and the therapeutic modalities, actual and theoretical.
Collapse
Affiliation(s)
- D S Rosenthal
- Harvard University Health Services, Cambridge, Massachusetts 02138
| |
Collapse
|
11
|
Abstract
The myeloproliferative disorders are a group of hematologic diseases that are believed to arise from somatic mutations in an early hematopoietic stem cell. This statement is based on the demonstration of monoclonal involvement of terminally differentiated myeloid and lymphoid elements. The techniques for establishing clonal derivation of cells are discussed and the application of these techniques to myeloproliferative diseases is reviewed. The evidence for limited myeloid involvement, lineage heterogeneity, in some patients with myeloproliferative disorders is summarized.
Collapse
Affiliation(s)
- K L Blanchard
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115
| | | | | |
Collapse
|
12
|
Abstract
Essential thrombocythemia is typically a disorder of adults in the sixth or seventh decade of life and is characterized by frequent thrombohemorrhagic complications. In young patients, the optimal management of complications is controversial. We studied 56 young adults (33 female and 23 male patients) with a diagnosis of essential thrombocythemia. The mean duration of follow-up was 4.68 years. The mean platelet count at diagnosis was 1,328,000/mm3. Platelet aggregation studies in 21 patients demonstrated hypoaggregation to epinephrine; spontaneous platelet aggregation was present in 4. At diagnosis, 39 patients were asymptomatic, and thrombocytosis was discovered incidentally. Throughout follow-up (up to 20 years), 24 patients remained asymptomatic. Thrombotic complications developed in 24 patients; they were life-threatening in only 3. The most common vaso-occlusive symptoms were migraine headache (in 12 patients) and erythromelalgia (in 3). Minor hemorrhagic complications occurred in six patients, and none was life-threatening. Serious complications (one cerebral and two myocardial infarctions) occurred in three patients, all of whom recovered. Two deaths occurred, neither of which was attributable to essential thrombocythemia. The treatment regimens used were chemotherapy in 9 patients, antiaggregating agents in 7, radioactive phosphorus in 1, the newer platelet-lowering agent anagrelide in 10, and only observation in 29. No treatment-related acute leukemias developed. This series of young patients with essential thrombocythemia, the largest to date, demonstrates a low incidence of life-threatening complications and a favorable long-term prognosis. Therapeutic recommendations should remain conservative, and potential leukemogens should be avoided unless serious complications develop. Anagrelide may be useful in young patients with thrombocythemia who are symptomatic.
Collapse
Affiliation(s)
- K J McIntyre
- Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905
| | | | | | | |
Collapse
|
13
|
Abstract
The diagnosis of essential thrombocythemia in a cat was made by fulfilling the five applicable criteria set forth by the Polycythemia Vera Study Group for use in humans. The criteria were 1) a platelet count persistently above 600,000/microL, 2) a normal initial hematocrit that did not rise in response to iron therapy, 3) normal serum iron concentration, 4) absence of collagen fibrosis of the bone marrow, and 5) no cause for reactive thrombocytosis. In addition, normal thrombopoietin concentrations and splenic hypofunction were demonstrated. Melphalan was not effective in decreasing the platelet count and the cat died of sepsis.
Collapse
Affiliation(s)
- A S Hammer
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Ohio State University, Columbus
| | | | | | | |
Collapse
|
14
|
Tablin F, Jain NC, Mandell CP, Hopper PE, Zinkl JG. Ultrastructural analysis of platelets and megakaryocytes from a dog with probable essential thrombocythemia. Vet Pathol 1989; 26:289-93. [PMID: 2763418 DOI: 10.1177/030098588902600401] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Blood platelets and bone marrow megakaryocytes from a dog with essential thrombocythemia were analyzed by transmission electron microscopy and compared with those of control dogs. Platelets varied in size and shape and contained enlarged and dilated open canalicular systems. Megakaryocytes were dysmorphic and had evidence of abnormal maturation, with large numbers of megakaryoblasts containing alpha granules and poorly organized and reduplicated demarcation membranes. The fewer, more mature megakaryocytes lacked normal cytoplasmic organization. Most notable was the absence of well-demarcated "platelet fields," due to the excessive and disorderly array of demarcation membranes.
Collapse
Affiliation(s)
- F Tablin
- Department of Anatomy, School of Veterinary Medicine, University of California-Davis
| | | | | | | | | |
Collapse
|
15
|
Wolf BC, Neiman RS. The Bone Marrow in Myeloproliferative and Dysmyelopoietic Syndromes. Hematol Oncol Clin North Am 1988. [DOI: 10.1016/s0889-8588(18)30591-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
16
|
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 11-1988. A 44-year-old woman with prominent thrombocytosis. N Engl J Med 1988; 318:691-8. [PMID: 3344020 DOI: 10.1056/nejm198803173181108] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
17
|
Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R, Boiron M. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986; 58:2440-7. [PMID: 3768838 DOI: 10.1002/1097-0142(19861201)58:11<2440::aid-cncr2820581115>3.0.co;2-y] [Citation(s) in RCA: 194] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
This retrospective study reviewed 94 patients, aged 6 to 90 years, with thrombocythemia. The women/men ratio was 1.76. At onset or, less commonly, during the course of the disease, 45% of the patients presented hemorrhagic manifestations, 29% thrombotic complications, and only 14% the association of hemorrhage and thrombosis. The average platelet count was 1200 X 10(9)/1, with no difference according to sex or age. Platelet hypoaggregation was seen in practically all the cases (94%), although myelofibrosis was less frequent (54%). The frequency of hemorrhages increased when the platelet count was above 1000 X 10(9)/1 (P less than 0.01), but the occurrence of thrombosis was correlated neither with platelet count nor with thrombopathy. Survival time was lengthy: 80% of survival (standard error 6%) was observed at 100 months. Transformation to acute leukemia was observed in five patients. Because the disease course is most often prolonged, therapeutic measures must be conservative: anti-aggregating drugs in small doses, and chemotherapy beginning with nonalkylating agents.
Collapse
|